Protein Forest Expands into Europe
News Jan 09, 2009
Protein Forest© announced that it has opened new business in Europe. Led by newly appointed Robert Marchmont, Ph.D. the European division will be headquartered in Newcastle upon Tyne, UK and will include office space and laboratory facilities to support sales, product demonstrations, applications development and collaborative projects with European customers.
Dr. Marchmont joins Protein Forest as European Business Director and brings with him over 25 years experience in the Life Science industry most recently with GE Healthcare. His particular focus on proteomics technologies and breadth of business expertise makes him an ideal appointment to this role.
“We are delighted to welcome Bob to the Protein Forest team and look forward to him setting up dedicated sales, a customer support team and distribution networks within Europe.” said Russell Garlick, Ph.D., President and CEO of Protein Forest. “There is growing confidence in the proteomics field applying our digital ProteomeChip (dPC™) sample preparation technology for mass spectrometry based proteomics and there are particular advantages to applying the dPC to aspects of targeted proteomics within clinical research.”
He added, “This confidence is highlighted particularly by the sustained investment we are receiving and customers’ purchases in such challenging times that exist today”.
Dr Marchmont commented, “I am delighted to be joining Protein Forest and to showcasing the benefits of our innovative product portfolio to European proteomic scientists. The Protein Forest dPC technology brings new advancements in data quality and speed to results for researchers applying mass spectrometry to their work.”
Watch: Could Digital Microfluidics Revolutionise Experimentation?News
Technology using 'programmable droplets' could enable automated research on a grand scale.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE